KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-Current Deffered Revenue: 2009-2020

Historic Non-Current Deffered Revenue for Rigel Pharmaceuticals (RIGL) over the last 9 years, with Sep 2020 value amounting to $146,000.

  • Rigel Pharmaceuticals' Non-Current Deffered Revenue fell 99.42% to $146,000 in Q3 2020 from the same period last year, while for Sep 2020 it was $146,000, marking a year-over-year decrease of 99.42%. This contributed to the annual value of $1.4 million for FY2019, which is 0.28% down from last year.
  • As of Q3 2020, Rigel Pharmaceuticals' Non-Current Deffered Revenue stood at $146,000, which was down 90.63% from $1.6 million recorded in Q1 2020.
  • In the past 5 years, Rigel Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $26.4 million in Q2 2019 and a low of $90,000 during Q4 2017.
  • Over the past 3 years, Rigel Pharmaceuticals' median Non-Current Deffered Revenue value was $1.4 million (recorded in 2018), while the average stood at $9.2 million.
  • In the last 5 years, Rigel Pharmaceuticals' Non-Current Deffered Revenue surged by 14,720.79% in 2019 and then tumbled by 99.42% in 2020.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Non-Current Deffered Revenue stood at $279,000 in 2016, then tumbled by 67.74% to $90,000 in 2017, then skyrocketed by 1,464.44% to $1.4 million in 2018, then decreased by 0.28% to $1.4 million in 2019, then crashed by 99.42% to $146,000 in 2020.
  • Its Non-Current Deffered Revenue was $146,000 in Q3 2020, compared to $1.6 million in Q1 2020 and $1.4 million in Q4 2019.